Taking your product successfully to market hinges on the talents of those developing it. Our scientists and professionals are among the top in the industry. We combine our experience and expertise to form an in-depth understanding of your product. We become an extension of your company, anticipating changes, overcoming challenges, and developing on-the-spot solutions for advancement. Our projects are characterized by timely communications and responsive action so the client is never unfavorably surprised. We go beyond simply delivering a product. As a team of innovative thinkers, we contribute our unique insight to quickly meet the specific challenges of your product. Our extensive train of equipment, responsive staff, and detailed scheduling processes ensure that your project will be completed with the highest level of quality, cost control and timeliness.
- John M. Gregory
- James E. Gregory
- Gary Hollenbeck
- Ed Scholtz
- Frances F. Spaven
- Richard Green
- Sean Brennan
- Herschel Blessing
- Muqeem Mughal
- John Bowles
John M. Gregory
Chairman and CEO, Gregory Pharmaceutical Holdings, Inc.
Serving as Chairman and CEO for UPM Pharmaceuticals, Inc., John M. Gregory is a pioneer in specialty pharmaceuticals. In 2002, John received the Ernst & Young Entrepreneur of the Year award, honored as the winner in the Health Sciences category. After graduating from the University of Maryland with a degree in pharmacy, John and his wife, Joan, moved to Bastian, Virginia, where he opened the town’s first retail pharmacy. Seeing an opportunity to expand, in 1984 John co-founded General Injectables and Vaccines (GIV), a company that supplied injectables and vaccine products directly to physicians’ offices. As president and CEO, John turned GIV into a successful enterprise with 550 employees and annual revenues exceeding $150 million annually. With a small initial investment in their pockets and a lot of debt on their shoulders, John and his brothers purchased a pharmaceutical manufacturing facility in Bristol, Tennessee, in 1993. Under John’s leadership as chairman and CEO from 1993-2001, King Pharmaceuticals grew from a 90-employee family business to an S&P 500 Index company on the New York Stock Exchange with revenues exceeding $1 billion.
James E. Gregory
President and CEO
James E. Gregory served as the President and Chief Operating Officer of UPM from 2004 to 2007. After retiring in January, 2008, he was reappointed to this position in October, 2009. Gregory previously worked for King Pharmaceuticals from 1995 to 2000 as Executive Vice President and General Manager of King’s Bristol, Tennessee manufacturing facility. He served in various consulting capacities at King from 2000 to 2003 and served on the Board of Directors in 2002 and 2003. Gregory served from 1982 to 1995 as a senior administrator in the court systems of Phoenix, Arizona and Washington, D.C. He was deputy executive officer in charge of business operations of the District of Columbia Court System from 1990 to 1995. Gregory has a B. A. from the University of Maryland and a masters in public administration from American University.
Gary Hollenbeck, PhD
Chief Scientific Officer
Dr. Hollenbeck has been a member of UPM’s senior management team since its inception in 1997 and he assumed the position of Chief Scientific Officer, January 1, 2006. He serves as a key scientific and technical advisor at UPM and personally directs focused research and development projects in the area of novel drug delivery platforms. Dr. Hollenbeck also currently oversees the technical services, manufacturing, and materials management groups at the Baltimore facility. Prior to assuming the full-time position at UPM, he was most recently Professor of Pharmaceutical Sciences at the University of Maryland School of Pharmacy. He received his B.S. degree from Albany College of Pharmacy and his Ph.D. in Industrial and Physical Pharmacy from Purdue University. Hollenbeck was Associate Dean for Academic Programs at the UM School of Pharmacy from 1991 to 1996, and was one of the principal architects of the School’s nationally recognized Doctor of Pharmacy program. During that period, he was also co-principal investigator on the UMAB/FDA Collaborative Agreement; a joint education, research and computer database effort aimed at establishing a scientific basis for review of new and amended drug applications. In this capacity, he and his associates received a Special Recognition Award for the SUPAC IR Training Program, from the Center for Drug Evaluation and Research, FDA, PHS, DHHS. Hollenbeck also served as a member of the Advisory Committee on Pharmaceutical Science, Office of Pharmaceutical Science at FDA and in 2003 received a DHHS, FDA Commissioner’s Special Citation for his work with the Center for Veterinary Medicine. Dr. Hollenbeck is a member of the Editorial Advisory Board for Pharmaceutical Technology and continues to serve as Adjunct Professor of Pharmaceutical Sciences at the UM School of Pharmacy.
Ed Scholtz, Ph.D.
Vice President, Research and Development
Dr. Scholtz is responsible for UPM’s Research and Development Division. He also personally manages numerous formulation and development projects. Prior to joining UPM, Dr. Scholtz enjoyed 22 years working in various sophisticated scientific and management positions for Merck & Company. These positions included site automation compliance, worldwide quality assurance, manufacturing division regulatory compliance, and pharmaceutical R&D leadership on large, complex, new product formulation/process development project teams. Dr. Scholtz is the co-author of four patents, numerous publications, and many presentations at professional meetings. He received his B.S. degree in Pharmacy from the University of Pittsburgh, an M.S. in Pharmaceutical Sciences from the same institution and his Ph.D. in Industrial and Physical Pharmacy from Purdue University.
Frances F. Spaven, PhD
Vice President, Drug Development Contract Services
Dr. Spaven oversees early stage Client-UPM project contracting, requests and deliverables. Prior to joining UPM, Dr. Spaven spent ten years with the Medical Products Business at E.I. DuPont de Nemours. Her assignments there included: Process Chemist in R&D, Manager of a cGMP Tablet and Blend production area, and Technical Manager of Specialty Reagents and Industrial Pharmacy Divisions. During this time, Dr. Spaven also participated on the following committees: ISO-9001 certification, Business Resource Planning, Product Development and Commercialization Framework, Consumables Product Approval Committee (CPAC), Medical Products Professional Progression Committee (PPC) and the Technology Advisory Panel. The CPAC reviewed and approved all new and revised products for funding and resourcing; the PPC recommended for approval all senior level technical promotions. The TAP evaluated and approved funding for new research and technology scouting efforts. Dr. Spaven also has contributed her time to programs such as Junior Achievement, Telementoring Science, and Education and Business Alliance; programs all aimed at encouraging young adults in science careers. Dr. Spaven earned her Ph.D. in Pharmaceutical Chemistry from the University of Maryland School of Pharmacy.
Vice President, Manufacturing
Richard Green serves as UPM’s Vice President of Manufacturing. Mr. Green has most recently served as site operations director for AAIPharma’s Wilmington, NC solid dose facility and their Charleston, SC parenteral facility. He has 10 years’ experience managing solid dose operations for AAIPharma and over 30 years’ experience in manufacturing operations for several well-known pharmaceutical companies. Mr. Green has worked in OTC, brand and generic manufacturing in the development and commercial production of solid dosage products. He also has 3 years’ experience in sterile and liquid manufacture as well. Richard has been involved in bringing nearly 30 drugs to market for a variety of companies/clients from their initial development through commercial launch, including either the transfer or process validation activities as well as dealing with FDA for routine or specific inspections (PAI/Validation). He received his Bachelor of Science Degree from the University of Tennessee.
Vice President, Quality Assurance
Vice President, Logistics
Herschel Blessing joined UPM as Vice President of Logistics in 2013. Mr. Blessing oversees distribution and inventory management and brings a wealth of experience in distribution and logistics having previously served as Senior Vice President, Logistics, for Graceway Pharmaceuticals, LLC from 2007 through 2011. His previous background includes serving as Executive Vice President of Logistics at SJ Strategic Investments and as Executive Vice President of Distribution at King Pharmaceuticals. Mr. Blessing has over twenty (20) years of experience in the pharmaceutical industry.
Director of Analytical Chemistry
Mr. Mughal has over 14 years’ experience in Analytical Chemistry with the past 8 years being spent in the pharmaceutical industry. He joined UPM in 2006, starting as a Senior Analytical Chemist before moving on to a Group Leader/Scientist role and then as the Manager of Analytical Chemistry, leading a team of analytical chemists to support the R&D group and the manufacturing group for testing of everything from raw materials to final product as well as performing method development, transfer and validations. Prior to joining UPM, Mr. Mughal has held QC/Analytical positions at FMC Corporation and Pharmaceutics International Inc. (PII). Mr. Mughal has a Bachelor of Science Degree (Honors) in Chemistry from University of Nairobi and a Master of Science Degree in Biotechnology from Johns Hopkins University.
Vice President, General Counsel
Mr. Bowles joined UPM as Vice President and General Counsel in 2013. Prior to joining UPM, Mr. Bowles served as Vice President and Corporate Counsel for Graceway Pharmaceuticals from 2007 through 2012. Mr. Bowles primarily works in the fields of corporate law and mergers and acquisitions. Mr. Bowles has overseen and handled multiple complex transactions and has appeared before the State Department, the United States Food & Drug Administration and the United States Environmental Protection Agency. Mr. Bowles was Associate General Counsel for Asahi’s North America operations from 2002 through 2007. Mr. Bowles received a J.D. from The University of Tennessee College of Law in 1994 and worked in private practice prior to joining Asahi in 2002.